Elanco Animal Health Future Growth
Future criteria checks 0/6
Elanco Animal Health is forecast to grow earnings and revenue by 1.6% and 3.8% per annum respectively. EPS is expected to grow by 0.6% per annum. Return on equity is forecast to be 6.5% in 3 years.
Key information
1.6%
Earnings growth rate
0.6%
EPS growth rate
Pharmaceuticals earnings growth | 23.9% |
Revenue growth rate | 3.8% |
Future return on equity | 6.5% |
Analyst coverage | Good |
Last updated | 13 Dec 2024 |
Recent future growth updates
Recent updates
Elanco Animal Health Incorporated's (NYSE:ELAN) Business And Shares Still Trailing The Industry
Dec 12Elanco Animal Health's (NYSE:ELAN) Solid Profits Have Weak Fundamentals
Nov 15Elanco Animal Health: Not Expensive, But Debt Remains An Issue
Nov 08Here's Why Elanco Animal Health (NYSE:ELAN) Has A Meaningful Debt Burden
Sep 22Elanco Animal Health Incorporated (NYSE:ELAN) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Sep 01Elanco Animal Health: Positioned For Success
Aug 16Investors Don't See Light At End Of Elanco Animal Health Incorporated's (NYSE:ELAN) Tunnel And Push Stock Down 27%
Jul 11Elanco Animal Health: Pipeline Concerns Appear Overblown
Jun 30Elanco Animal Health (NYSE:ELAN) Has A Somewhat Strained Balance Sheet
Jun 06Elanco Animal Health: At Least Fully Valued After Rally
Jun 05Benign Growth For Elanco Animal Health Incorporated (NYSE:ELAN) Underpins Its Share Price
Apr 22Elanco Animal Health (NYSE:ELAN) Seems To Be Using A Lot Of Debt
Feb 24Elanco Animal Health: A Solid Sale Addresses Leverage
Feb 09Elanco Animal Health Incorporated (NYSE:ELAN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 01Elanco Animal Health: Turning More Healthy
Dec 21Elanco Animal Health: Signs Of Stabilization, Amidst Still A Big Debt Pile
Oct 05Elanco Animal Health: Seems Like A Decent Bet Right Now
Jul 25Elanco Animal Health: Robust Results Overshadowed By Persisting Challenges
Jul 14Elanco Q4 2022 Earnings Preview
Feb 20Elanco's Tangible Equity Units: Living With The Worst Case
Dec 13Elanco Q3 2022 Earnings Preview
Nov 07Elanco Animal Health: This 'Sick Dog' Should Recover
Oct 19Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 4,757 | 99 | 531 | 723 | 10 |
12/31/2025 | 4,553 | 16 | 412 | 572 | 11 |
12/31/2024 | 4,433 | 320 | 218 | 677 | 11 |
9/30/2024 | 4,454 | 205 | 372 | 521 | N/A |
6/30/2024 | 4,492 | -1,255 | 425 | 557 | N/A |
3/31/2024 | 4,365 | -1,302 | 278 | 418 | N/A |
12/31/2023 | 4,417 | -1,231 | 117 | 271 | N/A |
9/30/2023 | 4,367 | -1,144 | -65 | 127 | N/A |
6/30/2023 | 4,324 | -113 | -87 | 118 | N/A |
3/31/2023 | 4,442 | -26 | 173 | 369 | N/A |
12/31/2022 | 4,411 | -78 | 268 | 452 | N/A |
9/30/2022 | 4,538 | -132 | 466 | 662 | N/A |
6/30/2022 | 4,644 | -171 | 387 | 562 | N/A |
3/31/2022 | 4,748 | -371 | 232 | 399 | N/A |
12/31/2021 | 4,764 | -483 | 286 | 483 | N/A |
9/30/2021 | 4,791 | -698 | -86 | 167 | N/A |
6/30/2021 | 4,550 | -729 | -366 | -34 | N/A |
3/31/2021 | 3,857 | -572 | -345 | -23 | N/A |
12/31/2020 | 3,271 | -574 | -352 | -41 | N/A |
9/30/2020 | 2,921 | -246 | -97 | 178 | N/A |
6/30/2020 | 2,802 | -101 | 147 | 330 | N/A |
3/31/2020 | 2,998 | -13 | 8 | 220 | N/A |
12/31/2019 | 3,071 | 68 | 27 | 224 | N/A |
9/30/2019 | 3,083 | 94 | 89 | 237 | N/A |
6/30/2019 | 3,073 | 144 | 207 | 362 | N/A |
3/31/2019 | 3,062 | 45 | 314 | 448 | N/A |
12/31/2018 | 3,067 | 87 | 351 | 487 | N/A |
9/30/2018 | 3,022 | -91 | 213 | 355 | N/A |
6/30/2018 | 2,958 | -172 | N/A | 267 | N/A |
3/31/2018 | 2,906 | -174 | N/A | 176 | N/A |
12/31/2017 | 2,889 | -311 | N/A | 174 | N/A |
12/31/2016 | 2,914 | -48 | N/A | 156 | N/A |
12/31/2015 | 2,909 | -211 | N/A | 7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ELAN's forecast earnings growth (1.6% per year) is below the savings rate (2.6%).
Earnings vs Market: ELAN's earnings (1.6% per year) are forecast to grow slower than the US market (15.2% per year).
High Growth Earnings: ELAN's earnings are forecast to grow, but not significantly.
Revenue vs Market: ELAN's revenue (3.8% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: ELAN's revenue (3.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ELAN's Return on Equity is forecast to be low in 3 years time (6.5%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 03:04 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Elanco Animal Health Incorporated is covered by 28 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jasper Hellweg | Argus Research Company |
Ishan Majumdar | Baptista Research |
Balaji Prasad | Barclays |